Row 53727

Row ID: 53727 | Dataset Entry | Axioma AXP Content Repository

Content Data

This page contains data entry 53727 from the Axioma AXP content repository. The structured data below represents the complete record for this entry.

MNMD hasn't been mentioned on any stock sub in years which is wild because Mind Medicine is a company that has a drug (mm10) that's in phase 2b clinical trials, and it's going well enough that the FDA granted it [Breakthrough Therapy designation](https://www.psychiatrictimes.com/view/fda-grants-breakthrough-designation-to-mm-120-for-generalized-anxiety-disorder) back in March for it's treatment of GAD or General Anxiety Disorder. It is a condition that affects [40 million Americans](https://www.forbes.com/health/mind/anxiety-statistics/#:~:text=Anxiety%20disorders%20are%20the%20most,with%206.8%20million%20adults%20affected) and that is a number that rises every fucking year. Feeling nervous?

Well you shouldn't, this company only wants to give you acid about it! **Literally** **a tartrate salt form of lysergide, a semi-synthetic hallucinogen commonly known as LSD**. Turns out it's showing to be crazy effective, not only for anxiety but also depression and that's a swath that covers 32% of Americans:

[While it was not the study’s primary purpose, results did show that MM120 also improved signs of depression Karlin said. “We saw rapid and robust improvement on depression symptoms in people — depression and anxiety have overlapping disease definitions."](https://www.cnn.com/2024/03/07/health/lsd-anxiety-fda-breakthrough-therapy-wellness/index.html#:~:text=While%20it%20was%20not%20the,anxiety%20have%20overlapping%20disease%20definitions.%E2%80%9D)

The breakthrough designation cuts the median time to get through trials to significantly and only 19% of treatments that apply are granted this status, so it kind of fucking rocks. That's exactly why the stock ran from $4 to $8 in March. At the same time the company did an offering which raised about 175 million. For the year ended December 31, 2023, net cash used in operating activities was **$64.4 million**, compared to $50.1 million for the year ended December 31, 2022. So, from a historic perspective, they're in a good cash position. I mean, as good of one as you can get with no fucking revenue amiright?

Check this out though, the LSD no-sad-stuff is just one of their therapies, they're also throwing MDMA (fucking molly) at people with the 'tism (Autism Spectrum Disorder)! MM-402 is shown to ["have a 91% phase transition success rate (PTSR) indication benchmark for progressing into Phase II."](https://www.pharmaceutical-technology.com/data-insights/mm-402-mind-medicine-mindmed-autism-spectrum-disorder-asd-likelihood-of-approval/?cf-view)

I have LEAPS for 2026 and am adding no fewer than 10 shares a week until something happens. The spread on LEAPS is kind of ass so maybe shares are the way to go? I don't know, I'm pretty regarded but this seems like a no brainer to buy and hold.

https://preview.redd.it/9qwk7niu522d1.png?width=1138&format=png&auto=webp&s=0c154f6e709098a0dfcda4c0f406c4312b0b6ac6

Field	Value
text	MNMD hasn't been mentioned on any stock sub in years which is wild because Mind Medicine is a company that has a drug (mm10) that's in phase 2b clinical trials, and it's going well enough that the FDA granted it [Breakthrough Therapy designation](https://www.psychiatrictimes.com/view/fda-grants-breakthrough-designation-to-mm-120-for-generalized-anxiety-disorder) back in March for it's treatment of GAD or General Anxiety Disorder. It is a condition that affects [40 million Americans](https://www…
label	r/wallstreetbets
dataType	post
communityName	r/wallstreetbets
datetime	2024-05-22
username_encoded	Z0FBQUFBQm5Lak1VdjVBUnRVOXFQSEp2d1cxRWZxZmxsd0pIMzJNb1ltYmdjSlo4ZkV1bmNwWmhLUTQtWFJ2R3hjR0I5MFdNTURPLVhubHh3ZzJLRVh0MWJfV1dpNmpGeFE9PQ==
url_encoded	Z0FBQUFBQm5Lak9rUy1nUTN1Rm1fTkt4MXZIZ1ZBSE9BcDhOU09qOHQtcGdTMUF6NG8zejRqMG9IejVqeGZ5YVRPLW1tYnhKcXh0S2t6OUUzZkMxN0xXcDc0WU9pVVRmUHhpYllueUdvSTFqTjhjMFNTT3I0STdGT1BBUnladl9XUUwtQnAzUUZ3R1F5M1k2ZWRWNFZ4ZHVFMDNnS21UQlpzUGs2cldZbzFReVFJSkV1SC1yMWhwY19IZHdsMkNoeEVpN3A0ckE3eWN0WXNtU2lMUmxfRlN6aXV2a1JBZG5OUT09

Raw Record

{
  "text": "MNMD hasn't been mentioned on any stock sub in years which is wild because Mind Medicine is a company that has a drug (mm10) that's in phase 2b clinical trials, and it's going well enough that the FDA granted it [Breakthrough Therapy designation](https://www.psychiatrictimes.com/view/fda-grants-breakthrough-designation-to-mm-120-for-generalized-anxiety-disorder) back in March for it's treatment of GAD or General Anxiety Disorder.  It is a condition that affects [40 million Americans](https://www.forbes.com/health/mind/anxiety-statistics/#:~:text=Anxiety%20disorders%20are%20the%20most,with%206.8%20million%20adults%20affected) and that is a number that rises every fucking year. Feeling nervous?\n\nWell you shouldn't, this company only wants to give you acid about it!  **Literally** **a tartrate salt form of lysergide, a semi-synthetic hallucinogen commonly known as LSD**. Turns out it's showing to be crazy effective, not only for anxiety but also depression and that's a swath that covers 32% of Americans:\n\n[While it was not the study’s primary purpose, results did show that MM120 also improved signs of depression Karlin said. “We saw rapid and robust improvement on depression symptoms in people — depression and anxiety have overlapping disease definitions.\"](https://www.cnn.com/2024/03/07/health/lsd-anxiety-fda-breakthrough-therapy-wellness/index.html#:~:text=While%20it%20was%20not%20the,anxiety%20have%20overlapping%20disease%20definitions.%E2%80%9D)\n\nThe breakthrough designation cuts the median time to get through trials to significantly and only 19% of treatments that apply are granted this status, so it kind of fucking rocks.   That's exactly why the stock ran from $4 to $8 in March.  At the same time the company did an offering which raised about 175 million.  For the year ended December 31, 2023, net cash used in operating activities was **$64.4 million**, compared to $50.1 million for the year ended December 31, 2022. So, from a historic perspective, they're in a good cash position. I mean, as good of one as you can get with no fucking revenue amiright?\n\nCheck this out though, the LSD no-sad-stuff is just one of their therapies, they're also throwing MDMA (fucking molly) at people with the 'tism (Autism Spectrum Disorder)! MM-402 is shown to [\"have a 91% phase transition success rate (PTSR) indication benchmark for progressing into Phase II.\"](https://www.pharmaceutical-technology.com/data-insights/mm-402-mind-medicine-mindmed-autism-spectrum-disorder-asd-likelihood-of-approval/?cf-view)\n\nI have LEAPS for 2026 and am adding no fewer than 10 shares a week until something happens. The spread on LEAPS is kind of ass so maybe shares are the way to go?  I don't know, I'm pretty regarded but this seems like a no brainer to buy and hold.\n\nhttps://preview.redd.it/9qwk7niu522d1.png?width=1138&format=png&auto=webp&s=0c154f6e709098a0dfcda4c0f406c4312b0b6ac6",
  "label": "r/wallstreetbets",
  "dataType": "post",
  "communityName": "r/wallstreetbets",
  "datetime": "2024-05-22",
  "username_encoded": "Z0FBQUFBQm5Lak1VdjVBUnRVOXFQSEp2d1cxRWZxZmxsd0pIMzJNb1ltYmdjSlo4ZkV1bmNwWmhLUTQtWFJ2R3hjR0I5MFdNTURPLVhubHh3ZzJLRVh0MWJfV1dpNmpGeFE9PQ==",
  "url_encoded": "Z0FBQUFBQm5Lak9rUy1nUTN1Rm1fTkt4MXZIZ1ZBSE9BcDhOU09qOHQtcGdTMUF6NG8zejRqMG9IejVqeGZ5YVRPLW1tYnhKcXh0S2t6OUUzZkMxN0xXcDc0WU9pVVRmUHhpYllueUdvSTFqTjhjMFNTT3I0STdGT1BBUnladl9XUUwtQnAzUUZ3R1F5M1k2ZWRWNFZ4ZHVFMDNnS21UQlpzUGs2cldZbzFReVFJSkV1SC1yMWhwY19IZHdsMkNoeEVpN3A0ckE3eWN0WXNtU2lMUmxfRlN6aXV2a1JBZG5OUT09"
}

Explore Dataset Explore Row

Entry Information

Entry ID: 53727
Repository: Axioma AXP
Dataset: arrmlet/reddit_dataset_36
Total Entries: 100,000